Ivermectin for COVID-19 : promising but not yet conclusive

Van Rensburg, Roland ; Decloedt, Eric H. ; Reuter, Helmuth ; Parker, Arifa ; Schrueder, Neshaad ; Lahri, Sa'ad (2021-03)

CITATION: Van Rensburg, R. et al. 2021. Ivermectin for COVID-19 : promising but not yet conclusive. South African Medical Journal, 111(3):188, doi:10.7196/SAMJ.2021.v111i3.15522.

The original publication is available at http://www.samj.org.za


Ivermectin has been proposed as a potential definitive and prophylactic treatment for COVID-19.[1] Ivermectin is an anthelmintic drug that is usually indicated for filarial and resistant scabies infections, but has been shown to have antiviral activity and anti-inflammatory activity in vitro.[2,3] Ivermectin has the potential to be a promising directed therapy in the drug armamentarium against COVID-19, as it has been shown to have in vitro activity against SARS-CoV-2.[4] Several randomised controlled trials (RCTs) and observational studies have reported on the effectiveness and safety outcomes of ivermectin in COVID-19.[1,5] These data are very promising, showing large treatment effects and acceptable adverse effect profiles for ivermectin against COVID-19, especially when combined in metaanalyses.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/110718
This item appears in the following collections: